{
    "cancer_info": {
        "cancer_name": "Chronic Myeloid Leukemia"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "History and physical exam (including spleen size)",
            "Complete blood count (CBC) with differential",
            "Chemistry profile (uric acid, electrolytes, liver/kidney function)",
            "Hepatitis B panel",
            "Bone marrow aspirate and biopsy (morphology assessment)",
            "Cytogenetic analysis (karyotyping for Philadelphia chromosome)",
            "Quantitative RT-PCR for BCR-ABL1 (International Scale)",
            "Fluorescence in situ hybridization (FISH) if inadequate metaphases",
            "BCR-ABL1 kinase domain mutation testing (for resistance/suboptimal response)",
            "Flow cytometry (if advanced phase suspected)",
            "Cerebrospinal fluid (CSF) analysis (for CNS symptoms)",
            "MRI/CT for extramedullary disease assessment",
            "Electrocardiogram (ECG) for nilotinib/ponatinib candidates",
            "Cardiovascular risk evaluation"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Chronic Phase (CP): <10% blasts in blood/bone marrow",
            "risk_group": "Low risk (Sokal/Euro/ELTS)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Older patients or those with comorbidities",
                    "plan_name": "Imatinib",
                    "plan_details": "400 mg/day orally",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard regimen"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Young patients aiming for treatment-free remission",
                    "plan_name": "Second-generation TKI",
                    "plan_details": "Dasatinib 50-100 mg/day, Nilotinib 300 mg BID, or Bosutinib 400 mg/day",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Chronic Phase (CP): <10% blasts in blood/bone marrow",
            "risk_group": "Intermediate/High risk (Sokal/Euro/ELTS)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Second-generation TKI",
                    "plan_details": "Dasatinib 100 mg/day, Nilotinib 300 mg BID, or Bosutinib 400 mg/day",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Accelerated Phase (AP): 10–19% blasts, basophils ≥20%, platelets <100 × 10⁹/L, or cytogenetic evolution",
            "risk_group": "Not applicable",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "TKI ± chemotherapy",
                    "plan_details": "Dasatinib, Nilotinib, Bosutinib, or Ponatinib ± disease-specific chemotherapy. Allogeneic HCT for eligible patients.",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Blast Phase (BP): ≥20% blasts or extramedullary disease",
            "risk_group": "Not applicable",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Lymphoid blast phase",
                    "plan_name": "Hyper-CVAD + TKI",
                    "plan_details": "Hyper-CVAD chemotherapy + Dasatinib (preferred for CNS penetration) with CNS prophylaxis, followed by allogeneic HCT",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Myeloid blast phase",
                    "plan_name": "AML-type chemotherapy + TKI",
                    "plan_details": "AML-type chemotherapy + TKI, followed by allogeneic HCT",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Resistant/Relapsed disease",
            "risk_group": "Mutation-specific",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "T315I mutation",
                    "plan_name": "Ponatinib or Asciminib",
                    "plan_details": "Ponatinib: 45 mg/day (reduce to 15 mg after response); Asciminib: 40 mg BID",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "F317L/V mutations",
                    "plan_name": "Nilotinib or Bosutinib",
                    "plan_details": "Avoid Dasatinib; Nilotinib 300 mg BID or Bosutinib 400 mg/day",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Mutation-adapted therapy"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Multi-TKI resistance",
                    "plan_name": "Allogeneic HCT",
                    "plan_details": "For eligible patients with resistance to ≥2 TKIs or advanced phase presentation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Treatment-free remission (TFR) attempt",
            "risk_group": "Deep molecular response",
            "treatment_plans": [
                {
                    "treatment_line": "Consolidation therapy",
                    "patient_subgroup": "Stable deep molecular response",
                    "plan_name": "TKI discontinuation",
                    "plan_details": "After ≥3 years TKI therapy and ≥2 years stable DMR (≤0.01% BCR-ABL1 IS). Monthly qPCR monitoring for 6 months post-discontinuation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Special circumstance"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "BCR-ABL1 transcript levels: ≤10% at 3 months predicts superior progression-free/overall survival; ≤1% at 12 months reduces progression risk",
            "Major Molecular Response (MMR ≤0.1% IS): Prerequisite for treatment-free remission attempts",
            "T315I mutation: Confers resistance to all TKIs except ponatinib/asciminib",
            "e1a2 transcript variant: Associated with lymphoid phenotype and inferior treatment responses",
            "Non-BCR-ABL1 mutations (ASXL1, RUNX1, IKZF1): Predict resistance and disease progression",
            "Cytogenetic evolution: Marker for accelerated/blast phase transformation"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：慢性髓性白血病.txt"
}